Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx

NCT ID: NCT00797290

Last Updated: 2017-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect outcomes information to see what effects photon/proton beam radiation has on nasopharynx cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharynx Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Photon/Proton Radiation Therapy

Photon/Proton Radiation Therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\* Nasopharynx cancer.

Exclusion Criteria

* Evidence of distant metastasis.
* Previous radiation for head and neck cancer.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roi Dagan, MD, MS

Role: PRINCIPAL_INVESTIGATOR

University of Florida Proton Therapy Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida Proton Therapy Institute

Jacksonville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Peters LJ. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):985-96. doi: 10.1016/s0360-3016(97)00104-1.

Reference Type BACKGROUND
PMID: 9169804 (View on PubMed)

Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, Ward PH. Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope. 1992 Sep;102(9):965-72. doi: 10.1288/00005537-199209000-00002.

Reference Type BACKGROUND
PMID: 1518360 (View on PubMed)

Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994 Jun;21(3):382-97. No abstract available.

Reference Type BACKGROUND
PMID: 8209270 (View on PubMed)

Teo PM, Chan AT, Lee WY, Leung TW, Johnson PJ. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71. doi: 10.1016/s0360-3016(98)00383-6.

Reference Type BACKGROUND
PMID: 10030248 (View on PubMed)

Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7. doi: 10.1200/JCO.1998.16.4.1310.

Reference Type BACKGROUND
PMID: 9552031 (View on PubMed)

Cooper JS, Lee H, Torrey M, Hochster H. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):861-6. doi: 10.1016/s0360-3016(00)00558-7.

Reference Type BACKGROUND
PMID: 10863053 (View on PubMed)

Mendenhall WM, Riggs CE Jr, Cassisi NJ: Treatment of head and neck cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005., pp 662-732.

Reference Type BACKGROUND

Laramore GE, ed.: Radiation Therapy of Head and Neck Cancer. Berlin: Springer-Verlag, 1989.

Reference Type BACKGROUND

Cummings CW, Fredrickson JM, Harker LA, et al.: Otolaryngology - Head and Neck Surgery. Saint Louis, Mo: Mosby-Year Book, Inc., 1998.

Reference Type BACKGROUND

Marks JE, Bedwinek JM, Lee F, Purdy JA, Perez CA. Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer. 1982 Sep 15;50(6):1042-50. doi: 10.1002/1097-0142(19820915)50:63.0.co;2-y.

Reference Type BACKGROUND
PMID: 7104948 (View on PubMed)

Vikram B, Mishra UB, Strong EW, Manolatos S. Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1455-9. doi: 10.1016/0360-3016(85)90332-3.

Reference Type BACKGROUND
PMID: 3926733 (View on PubMed)

Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):329-37. doi: 10.1016/s0360-3016(00)00585-x.

Reference Type BACKGROUND
PMID: 10974445 (View on PubMed)

Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22. doi: 10.1016/s0360-3016(02)02724-4.

Reference Type BACKGROUND
PMID: 12007936 (View on PubMed)

Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63. doi: 10.1016/0360-3016(94)90346-8.

Reference Type BACKGROUND
PMID: 7960976 (View on PubMed)

Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):765-73. doi: 10.1016/0360-3016(94)90347-6.

Reference Type BACKGROUND
PMID: 7960977 (View on PubMed)

Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM. Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1070-7. doi: 10.1016/j.ijrobp.2004.12.009.

Reference Type BACKGROUND
PMID: 15990010 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UFPTI 0605-NP01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Proton Therapy for Hodgkin Lymphoma
NCT00850200 COMPLETED NA
Daily vs. Non-Daily SBRT for NSCLC
NCT03624907 TERMINATED NA